The investigators plan to randomise participants to receive ketamine or placebo control
subcutaneously or by 40-minute intravenous infusions and will follow them up for 42 days to
assess the incidence of postpartum depression. This feasibility pilot study is designed to
explore the adequacy of the study procedures and tolerability of the interventions.